EU Ban Triggers Crisis in Global Biopharmaceutical Industry: Battle for Triton™X-100 Alternatives Begins!

The European Union's ban on a chemical called Triton™X-100 has already had a profound impact on the biopharmaceutical manufacturing industry worldwide. The ban stems from the potential harm the Triton™X-100 can cause to aquatic life, and as a result, it was officially banned by the European Union in 2021. Thankfully, however, the market has responded quickly to provide superior performance alternatives to meet the needs of the biopharmaceutical industry.

This message was delivered by Dr. Wenyi Yee, a research manager at Croda, and his colleague, principal Application Scientist Dr. Garima Sinha, in a presentation at the BioProcess International conference last month. Dr. Sinha stressed that while the ban on Triton™X-100 appears to only affect continental Europe, due to the global nature of the biopharmaceutical industry, any regional impact can evolve into a global issue.

Triton™X-100 is a detergent that has long been used in the production of biologics and plasma-derived products to prevent viral contamination. However, due to its potential harm to the environment, the European Union decided to put it on the banned list. This decision has forced the pharmaceutical industry to find new solutions to ensure the safety and effectiveness of the manufacturing process.

Initially, many companies based outside the EU were not enthusiastic about finding alternatives, as they had already invested decades of time and effort in optimizing their production processes based on the Triton™X-100. Dr Sinha points out that changing an existing production process is not easy, especially when an already well-established process needs to be revisited.

However, as the industry continues to investigate alternatives to the Triton™X-100, a number of viable technical solutions have emerged. These alternative techniques include using different detergents, or exposing the cells to low pH to remove viral contamination and lyse the cells. Nevertheless, Dr. Sinha believes that detergents are a better option than pH changes because they are more powerful at removing viral contamination and have a lower risk of protein aggregation.

In preparation for the upcoming ban, Croda conducted a thorough review of its specialty chemicals catalog and successfully identified two chemicals that performed as well or better than the Triton™X-100. Last year, the company introduced two new products, Virodex™ TCR-1 and TCR-2. According to Dr. Yee, customers are currently trialling these products, and independent data has been published showing that Virodex performs as well as the Triton X-100 in production, and in some ways outperforms it.

In addition, Croda has developed advanced analytical technology capable of detecting Virodex™ at the parts per billion (PPB) level to ensure that its products do not contaminate the final drug. Dr Sinha explained that they have been working with customers to conduct analytical tests on samples to ensure the safety and reliability of the product. This initiative not only demonstrates Croda's commitment to product quality, but also provides the biopharmaceutical industry with a reliable solution to the challenges posed by the Triton™X-100 ban.